Gracheva N M, Gavrilov A F, Solov'eva A I, Smirnov V V, Sorokulova I B, Reznik S R, Chudnovskaia N V
Gabrichevsky Research Institute of Epidemiology and Microbiology, Moscow, Russia.
Zh Mikrobiol Epidemiol Immunobiol. 1996 Jan-Feb(1):75-7.
The clinico-laboratory study of the new probiotic Biosporin revealed its effectiveness in the treatment of patients with acute enteric infections. The pronounced curative action of the preparation, manifested by the rapid normalization of stool, the disappearance of abdominal pains and the decrease of dysbiosis in the intestine, was demonstrated. The best results were registered after the administration of Biosporin containing 2 x 10(9) microbial cells (Bacillus subtilis and Bacillus licheniformis). Biosporin was well tolerated by the patients, no side effects were observed. Biosporin is recommended for use in medical practice for the treatment of patients with acute enteric infections.
新型益生菌生物孢菌素的临床实验室研究表明，其对急性肠道感染患者的治疗具有有效性。该制剂具有显著的治疗作用，表现为大便迅速恢复正常、腹痛消失以及肠道菌群失调减轻。服用含有2×10⁹个微生物细胞（枯草芽孢杆菌和地衣芽孢杆菌）的生物孢菌素后取得了最佳效果。患者对生物孢菌素耐受性良好，未观察到副作用。建议在医疗实践中使用生物孢菌素治疗急性肠道感染患者。
